Related Experiment Video
Updated: Jan 19, 2026
06:30
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
911
Etanercept for chronic progressive cutaneous sarcoidosis
Chanisada Tuchinda1, Henry K Wong
1Department of Dermatology, Henry Ford Hospital, Detroit, MI 48202, USA.
Journal of Drugs in Dermatology : JDD
|June 16, 2006
Summary
Chronic cutaneous sarcoidosis, a challenging condition, often requires systemic treatments with potential side effects. This study highlights etanercept as a promising monotherapy for recalcitrant sarcoidosis skin lesions.
Area of Science:
- Dermatology
- Immunology
- Rheumatology
Background:
- Sarcoidosis is a multisystem granulomatous disease with diverse skin manifestations.
- Chronic cutaneous sarcoidosis presents management challenges, often necessitating systemic immunosuppressants.
- Conventional therapies like corticosteroids carry risks of side effects and long-term complications.
Observation:
- A 43-year-old patient with progressive chronic cutaneous sarcoidosis was studied.
- The patient had failed to respond to prior systemic steroid and immunosuppressive treatments.
Findings:
- Etanercept monotherapy led to significant improvement in cutaneous sarcoidosis lesions.
- This indicates a potential role for biologic agents in refractory cases.
Implications:
- Etanercept may be an effective alternative for patients with difficult-to-treat cutaneous sarcoidosis.
- Further research into biologic therapies for sarcoidosis is warranted.
- This case highlights the need for personalized treatment strategies in chronic inflammatory diseases.
